Skip to content
Screener

Treace Medical Concepts, Inc. TMCI Q2 2025 earnings

Reported August 7, 2025 · After market close

Revenue$47.4MMiss by $2.5M
EPS-$0.28Beat by $0.01
Revenue estimate$49.9M
EPS estimate-$0.29

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$47.7M
EPS estimate-$0.26

Financials

Q2 2025

Income statement

See full
Revenue$47.4M+6.6%
Gross profit$37.8M+5.8%
Operating income-$17.0M+20.6%
Net income-$17.4M+18.0%
EPS (diluted)-$0.28+17.6%

Balance sheet

See full
Cash & equivalents$8.1M-55.7%
Total debt$70.1M+0.3%
Total equity$97.6M-13.0%
Total assets$206.4M-8.7%

Cash flow

See full
Operating cash flow-$3.1M+78.1%
CapEx$4.8M+176%
Free cash flow-$7.8M+50.0%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$372.4M-9.4%
Enterprise value$434.44M-6.1%
P/S1.7×-0.3×

Profitability

See full
Gross margin80.1%-0.6pp
Operating margin-22.4%-5.4pp
Net margin-23%-5.1pp
FCF margin-13.6%-3.5pp

Returns & leverage

See full
Return on equity-46.9%-1.6pp
Debt / equity0.7×+0.1×
Current ratio3.5×-0.3×

FAQ

When did Treace Medical Concepts, Inc. report Q2 2025 earnings?
Treace Medical Concepts, Inc. (TMCI) reported Q2 2025 earnings on August 7, 2025 after market close.
What were Treace Medical Concepts, Inc.'s Q2 2025 revenue and EPS?
Treace Medical Concepts, Inc. reported revenue of $47.4M and eps of $-0.28 for Q2 2025.
Did Treace Medical Concepts, Inc. beat estimates in Q2 2025?
Revenue missed the consensus estimate of $49.9M by $2.5M. EPS beat the consensus estimate of $-0.29 by $0.01.
How did Treace Medical Concepts, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 6.6% from $44.5M a year earlier and eps grew 17.6% from $-0.34.
Where can I find Treace Medical Concepts, Inc.'s Q2 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-105039) and the 10-Q periodic report (0000950170-25-105059) directly on SEC EDGAR. The filing index links above go to sec.gov.